Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article
Acute coronary syndrome (ACS) is one of the most common leading global causes of mortality, encompassing ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina (UA). Percutaneous coronary intervention (PCI) has become a pivota...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Cardiovascular Therapeutics |
| Online Access: | http://dx.doi.org/10.1155/cdr/5549914 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825199970953723904 |
|---|---|
| author | Guiping Wang Kaijie Qi Xuyang Li Shuping Zuo Ruolin Zhang Yanan Zhao Suya Sun Juanjuan Zhang Xiaokun Liu |
| author_facet | Guiping Wang Kaijie Qi Xuyang Li Shuping Zuo Ruolin Zhang Yanan Zhao Suya Sun Juanjuan Zhang Xiaokun Liu |
| author_sort | Guiping Wang |
| collection | DOAJ |
| description | Acute coronary syndrome (ACS) is one of the most common leading global causes of mortality, encompassing ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina (UA). Percutaneous coronary intervention (PCI) has become a pivotal therapeutic approach for ACS, underscoring the importance of anticoagulation strategies. Among the commonly employed anticoagulants in PCI, heparin and bivalirudin take precedence, with heparin serving as the archetypal choice. Nevertheless, the determination of an optimal anticoagulation regimen remains a point of contention in contemporary clinical practice. To address the differences in anticoagulants during PCI, we meticulously conducted a literature review through PubMed and Web of Science, employing search terms such as “heparin,” “bivalirudin,” “percutaneous coronary intervention,” and “acute coronary syndrome.” For patients with PIC brought on by STEMI, NSTEMI, and stable or UA pectoris, the review focused on randomized controlled trials to assess and compare the efficacy and safety of heparin and bivalirudin as anticoagulant options. This systematic review is aimed at furnishing valuable insights into the ongoing debate surrounding the choice of anticoagulation regimens in PCI. By scrutinizing clinical evidence derived from relevant trials, we seek to inform and guide healthcare practitioners in making informed decisions based on the unique requirements of patients with various ACS presentations. |
| format | Article |
| id | doaj-art-a056a97e7c274c3890dd764522042468 |
| institution | Kabale University |
| issn | 1755-5922 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiovascular Therapeutics |
| spelling | doaj-art-a056a97e7c274c3890dd7645220424682025-02-08T00:00:07ZengWileyCardiovascular Therapeutics1755-59222024-01-01202410.1155/cdr/5549914Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review ArticleGuiping Wang0Kaijie Qi1Xuyang Li2Shuping Zuo3Ruolin Zhang4Yanan Zhao5Suya Sun6Juanjuan Zhang7Xiaokun Liu8Department of CardiologySchool of Public HealthDepartment of CardiologyDepartment of CardiologyHarvard T.H. Chan School of Public HealthDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyAcute coronary syndrome (ACS) is one of the most common leading global causes of mortality, encompassing ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina (UA). Percutaneous coronary intervention (PCI) has become a pivotal therapeutic approach for ACS, underscoring the importance of anticoagulation strategies. Among the commonly employed anticoagulants in PCI, heparin and bivalirudin take precedence, with heparin serving as the archetypal choice. Nevertheless, the determination of an optimal anticoagulation regimen remains a point of contention in contemporary clinical practice. To address the differences in anticoagulants during PCI, we meticulously conducted a literature review through PubMed and Web of Science, employing search terms such as “heparin,” “bivalirudin,” “percutaneous coronary intervention,” and “acute coronary syndrome.” For patients with PIC brought on by STEMI, NSTEMI, and stable or UA pectoris, the review focused on randomized controlled trials to assess and compare the efficacy and safety of heparin and bivalirudin as anticoagulant options. This systematic review is aimed at furnishing valuable insights into the ongoing debate surrounding the choice of anticoagulation regimens in PCI. By scrutinizing clinical evidence derived from relevant trials, we seek to inform and guide healthcare practitioners in making informed decisions based on the unique requirements of patients with various ACS presentations.http://dx.doi.org/10.1155/cdr/5549914 |
| spellingShingle | Guiping Wang Kaijie Qi Xuyang Li Shuping Zuo Ruolin Zhang Yanan Zhao Suya Sun Juanjuan Zhang Xiaokun Liu Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article Cardiovascular Therapeutics |
| title | Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article |
| title_full | Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article |
| title_fullStr | Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article |
| title_full_unstemmed | Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article |
| title_short | Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article |
| title_sort | heparin and bivalirudin in percutaneous coronary intervention for acute coronary syndromes a review article |
| url | http://dx.doi.org/10.1155/cdr/5549914 |
| work_keys_str_mv | AT guipingwang heparinandbivalirudininpercutaneouscoronaryinterventionforacutecoronarysyndromesareviewarticle AT kaijieqi heparinandbivalirudininpercutaneouscoronaryinterventionforacutecoronarysyndromesareviewarticle AT xuyangli heparinandbivalirudininpercutaneouscoronaryinterventionforacutecoronarysyndromesareviewarticle AT shupingzuo heparinandbivalirudininpercutaneouscoronaryinterventionforacutecoronarysyndromesareviewarticle AT ruolinzhang heparinandbivalirudininpercutaneouscoronaryinterventionforacutecoronarysyndromesareviewarticle AT yananzhao heparinandbivalirudininpercutaneouscoronaryinterventionforacutecoronarysyndromesareviewarticle AT suyasun heparinandbivalirudininpercutaneouscoronaryinterventionforacutecoronarysyndromesareviewarticle AT juanjuanzhang heparinandbivalirudininpercutaneouscoronaryinterventionforacutecoronarysyndromesareviewarticle AT xiaokunliu heparinandbivalirudininpercutaneouscoronaryinterventionforacutecoronarysyndromesareviewarticle |